检索结果-南通市图书馆

Sodium glucose cotransporter 2 inhibitors in the management of heart failure:Veni,Vidi,and Vici

World Journal of Cardiology 2024年第10期16卷 550-563页

作者： Monika Bhandari Akshyaya Pradhan Pravesh Vishwakarma Abhishek Singh Rishi Sethi Department of Cardiology King Georg’s Medical UniversityLucknow 226003Uttar PradeshIndia

heart failure(HF)is a chronic disease associated with high morbidity and mortality ***-angiotensin-aldosterone system blockers(including angiotensin receptor/neprilysin inhibitors),beta-blockers,and mineralocorticoid receptor blockers remain the mainstay of pharmacotherapy for HF with reduced ejection fraction(HFrEF).However,despite the use of guideline-directed medical therapy,the mortality from HFrEF remains *** with preserved ejection fraction(HFpEF)comprises approximately half of the total incident HF cases;however,unlike HFrEF,there are no proven therapies for this *** glucose cotransporter-2 inhibitors(SGLT-2is)represent a new class of pharmacological agents approved for diabetes mellitus(DM)that inhibit SGLT-2 receptors in the kidney.A serendipitous finding from seminal trials of SGLT-2is in DM was the significant improvement in renal and cardiovascular(CV)*** importantly,the improvement in HF hospitalization(HHF)in the CV outcomes trials of SGLT-2is was *** mechanisms have been proposed for the pleiotropic effects of SGLT-2is beyond their glycemic ***,as patients with HF were not included in any of these trials,it can be considered as a primary ***,two landmark studies of SGLT-2is in patients with HFrEF,namely,an empagliflozin outcome trial in patients with chronic HF and a reduced ejection fraction(EMPEROR-Reduced)and dapagliflozin and prevention of adverse outcomes in HF(DAPA-HF),demonstrated significant improvement in HHF and CV mortality regardless of the presence of *** impressive results pitchforked these drugs as class I indications in patients with HFrEF across major ***,empagliflozin outcome trial in patients with chronic HF with preserved ejection fraction(EMPEROR-Preserved)and dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction HF(DELIVER)trials successively confirmed that SGLT-2is also benefit patients w

关键词： heart failure with preserved ejection fraction Gliflozins Diuresis Natriuresis N terminal-pro brain natriuretic peptide heart failure hospitalization

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Elevated level of high-sensitivity cardiac troponin I as a predictor of adverse cardiovascular events in patients with heart failure with preserved ejection fraction

引用

Chinese Medical Journal 2023年第18期136卷 2195-2202页

作者： Hongyu Hu Jingjin Li Xin Wei Jia Zhang Jiayu Wang Department of Cardiovascular Beijing Tiantan HospitalCapital Medical UniversityBeijing 100070China Department of Neurology Beijing Tiantan HospitalCapital Medical UniversityBeijing 100070China Department of Neurocardiology Beijing Tiantan HospitalCapital Medical UniversityBeijing 100070China

Background:The relationship between the elevation of cardiac troponin and the increase of mortality and hospitalization rate in patients with heart failure with reduced ejection fraction is *** study investigated the association between the extent of elevated levels of high-sensitivity cardiac troponin I(hs-cTnI)and the prognosis in heart failure with preserved ejection fraction ***:A retrospective cohort study consecutively enrolled 470 patients with heart failure with preserved ejection fraction from September 2014 to August *** to the level of hs-cTnI,the patients were divided into the elevated level group(hs-cTnI>0.034 ng/mL in male and hs-cTnI>0.016 ng/mL in female)and the normal level *** of the patients were followed up once every 6 *** cardiovascular events were cardiogenic death and heart failure ***:The mean follow-up period was 36.2±7.9 *** mortality(18.6%[26/140]vs.1.5%[5/330],Pheart failure(HF)hospitalization rate(74.3%[104/140]vs.43.6%[144/330],Phospitalization(HR:3.254,95%CI:2.698-3.923,Phospitalization in heart failure with preserved ejection fraction patients.

关键词： heart failure with preserved ejection fraction High-sensitivity cardiac troponin I Cardiogenic mortality heart failure hospitalization

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：